Literature DB >> 1958493

Late vascular complications after bone marrow transplantation for dyskeratosis congenita.

C Berthou1, A Devergie, M F D'Agay, E Sonsino, M L Scrobohaci, C Loirat, E Gluckman.   

Abstract

Entities:  

Mesh：

Year:  1991        PMID： 1958493     DOI： 10.1111/j.1365-2141.1991.tb04543.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  7 in total

Review 1.  Pathophysiology and management of inherited bone marrow failure syndromes.

Authors:  Akiko Shimamura; Blanche P Alter
Journal:  Blood Rev       Date:  2010-04-24       Impact factor: 8.250

2.  Treatment of the hematological manifestations of dyskeratosis congenita.

Authors:  C Putterman; R Safadi; J Zlotogora; R Banura; A Eldor
Journal:  Ann Hematol       Date:  1993-04       Impact factor: 3.673

3.  Dyskeratosis congenita.

Authors:  Sharon A Savage; Blanche P Alter
Journal:  Hematol Oncol Clin North Am       Date:  2009-04       Impact factor: 3.722

Review 4.  Evaluation and Management of Hematopoietic Failure in Dyskeratosis Congenita.

Authors:  Suneet Agarwal
Journal:  Hematol Oncol Clin North Am       Date:  2018-05-28       Impact factor: 3.722

5.  A Reduced-Intensity Conditioning Regimen for Patients with Dyskeratosis Congenita Undergoing Hematopoietic Stem Cell Transplantation.

Authors:  Adam S Nelson; Rebecca A Marsh; Kasiani C Myers; Stella M Davies; Sonata Jodele; Tracey A O'Brien; Parinda A Mehta
Journal:  Biol Blood Marrow Transplant       Date:  2016-02-01       Impact factor: 5.742

Review 6.  The genetics and clinical manifestations of telomere biology disorders.

Authors:  Sharon A Savage; Alison A Bertuch
Journal:  Genet Med       Date:  2010-12       Impact factor: 8.822

7.  Busulphan-cyclophosphamide cause endothelial injury, remodeling of resistance arteries and enhanced expression of endothelial nitric oxide synthase.

Authors:  Sulaiman Al-Hashmi; Piet J M Boels; Fahad Zadjali; Behnam Sadeghi; Johan Sällström; Kjell Hultenby; Zuzana Hassan; Anders Arner; Moustapha Hassan
Journal:  PLoS One       Date:  2012-01-27       Impact factor: 3.240
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.